TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22279214

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) following continuous theta burst stimulation (cTBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive motor training of the nontarget hand without MVF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS) over the M1
Number of subjects: 0
Study: 20166008

Group type: EXPERIMENTAL
Intervention: Increasing the number of steps walked each day for 24 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Brisk walking at target heart rate for 20 min or more on two or more days a week
Number of subjects: 174
Study: 19548513

Group type: EXPERIMENTAL
Intervention: Computer-based decision support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative financing strategies for decision support systems
Number of subjects: 0
Study: 15982464

Group type: EXPERIMENTAL
Intervention: 5 day training course in aggression management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12652260

Group type: EXPERIMENTAL
Intervention: i.v. verapamil (50 mg in 500 cc saline solution at 40 ml/hr)
Number of subjects: 24

Group type: COMPARATOR
Intervention: i.v. amiodarone (300 mg in bolus followed by 900 mg in 500 cc 5% glucosate solution, 33 ml/hr for 6 hours and subsequently 18 ml/hr)
Number of subjects: 24
Study: 10480503

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 42

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 42
Study: 8671371

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 55

Group type: COMPARATOR
Intervention: urinary FSH (uFSH)
Number of subjects: 55
Study: 1684154

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microgram/kg (DXM1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.2 micrograms/kg (DXM2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam 80 micrograms/kg (MID)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 31002997

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 66

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 66
Study: 30223190

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 258
Study: 26644369

Group type: EXPERIMENTAL
Intervention: Evening intake of rivaroxaban (10 mg)
Number of subjects: 16
Study: 24958624

Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silver alloy-coated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard polytetrafluoroethylene (PTFE)-coated catheters
Number of subjects: 0
Study: 22646064

Group type: EXPERIMENTAL
Intervention: NaP tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEG with sodium picosulfate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NaP tablets and PEG with sodium picosulfate
Number of subjects: 100
Study: 20216569

Group type: EXPERIMENTAL
Intervention: Gelatin protein (0.6 g protein per kg bodyweight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy protein (0.6 g protein per kg bodyweight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin protein (0.6 g protein per kg bodyweight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Milk protein (0.6 g protein per kg bodyweight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 8
Study: 19089198

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.25 W, 20 Hz, 2.84 J/cm(2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.50 W, 20 Hz, 5.68 J/cm(2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.75 W, 20 Hz, 8.52 J/cm(2)
Number of subjects: 15
Study: 16003543

Group type: EXPERIMENTAL
Intervention: ECG-guided CVC placement
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard practice)
Number of subjects: 200
Study: 11818152

Group type: EXPERIMENTAL
Intervention: Cold-adapted live influenza vaccine (AA-LIV)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 5000
Study: 10081529

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 7743684

Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2099751

Group type: EXPERIMENTAL
Intervention: High-dose intermittent method (trt 1)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Moderate-dose continuous method (trt 2)
Number of subjects: 214
Study: 6800028

Group type: EXPERIMENTAL
Intervention: Combined treatment with synthetic human calcitonin (HCT 0.5 mg s.c./day, 5‐‐7 days per week) and EHDP (7.5 mg/kg, p.o.) for a mean duration of 6.1 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: HCT alone
Number of subjects: 23
Study: 30870779

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 28859603

Group type: EXPERIMENTAL
Intervention: Treadmill training with load to restrain the non-paretic ankle (experimental group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treadmill training without load (control group)
Number of subjects: 38
Study: 27480431

Group type: EXPERIMENTAL
Intervention: Two phase treatment (Herbst and fixed appliance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed appliance treatment only (edgewise appliance)
Number of subjects: 30
Study: 25493493

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (10 sessions at specific points for smoking)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Auriculotherapy (points that have no effect on the focus of research)
Number of subjects: 30
Study: 22579230

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (PD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No peritoneal drainage (Control)
Number of subjects: 69
Study: 19711585

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16644621

Group type: EXPERIMENTAL
Intervention: Structured personal care (women)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Routine care (women)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Structured personal care (men)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Routine care (men)
Number of subjects: 874
Study: 12926604

Group type: EXPERIMENTAL
Intervention: 1% permethrin cream rinse
Number of subjects: 701

Group type: COMPARATOR
Intervention: 0.4% d‐phenothrin shampoo
Number of subjects: 701
Study: 10688391

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g by intermittent bolus q12h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefepime 3 g by continuous infusion over 24 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefepime 4 g by continuous infusion over 24 hours
Number of subjects: 12
Study: 8656324

Group type: EXPERIMENTAL
Intervention: High unrealistic control belief
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low realistic control belief and high unrealistic control belief
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very high controllability hassles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low controllability hassles
Number of subjects: 0
Study: 1511641

Group type: EXPERIMENTAL
Intervention: Subcutaneous lateral internal sphincterotomy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Open lateral internal sphincterotomy
Number of subjects: 112
Study: 6361251

Group type: EXPERIMENTAL
Intervention: Cefamandole (administered intravenously after cord clamping)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31550802

Group type: EXPERIMENTAL
Intervention: Heat preserving group (H group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-heat preserving group (N group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: N group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: H group
Number of subjects: 60
Study: 28590358

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 603
Study: 26702168

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 23103527

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 204
Study: 21728433

Group type: EXPERIMENTAL
Intervention: PHLAME team intervention
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 397
Study: 19930436

Group type: EXPERIMENTAL
Intervention: Pathways Triple P (PTP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 60
Study: 16567607

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 100 mg/d
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 25 mg/d
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 15482037

Group type: EXPERIMENTAL
Intervention: Early Diet (ED) for the first 8 weeks
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Late Diet (LD) for the final 8 weeks
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Behavioral weight control after smoking quit date
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (no weight management)
Number of subjects: 315
Study: 11535971

Group type: EXPERIMENTAL
Intervention: Neltenexine (1 tablet twice daily for 20 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1 tablet twice daily for 20 days)
Number of subjects: 60
Study: 9575677

Group type: EXPERIMENTAL
Intervention: HLA‐B5 antigen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HLA‐DR7 antigen
Number of subjects: 71

Group type: COMPARATOR
Intervention: HLA haplotype B5‐DR5
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HLA haplotypes A2‐B12, B5‐DR2, and B12‐DR4
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HLA haplotypes A1‐B5 and B5‐DR5
Number of subjects: 71

Group type: COMPARATOR
Intervention: HLA haplotype A2‐B5‐DR5
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HLA haplotype A2‐B12‐DR4
Number of subjects: 71
Study: 8142091

Group type: EXPERIMENTAL
Intervention: 1.3 MAC sevoflurane alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.9 MAC sevoflurane with 0.4 MAC N2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.5 MAC sevoflurane alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.1 MAC sevoflurane with 0.4 MAC N2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sevoflurane and N2O combined
Number of subjects: 10
Study: 2907823

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: salazosulphapyridine (SASP)
Number of subjects: 11
Study: 28623524

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 106
Study: 26892612

Group type: EXPERIMENTAL
Intervention: Vaccination with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA‐A2+‐restricted peptides and Montanide, 6 doses every two weeks and a recall dose after 3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vaccination for compassionate use
Number of subjects: 14
Study: 25700993

Group type: EXPERIMENTAL
Intervention: Extraction of deciduous canine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-extraction
Number of subjects: 67
Study: 24078541

Group type: EXPERIMENTAL
Intervention: Augmented group (1 ml of bone cement injected into the screw hole before insertion of the screw)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-augmented group (no bone cement used)
Number of subjects: 16
Study: 20578534

Group type: EXPERIMENTAL
Intervention: High-fat meal (50.1 g total fat)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-fat meal (5.1 g total fat)
Number of subjects: 19
Study: 18234086

Group type: EXPERIMENTAL
Intervention: Intranasal TNFalpha (10 microg)
Number of subjects: 0
Study: 17036556

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12716663

Group type: EXPERIMENTAL
Intervention: DG treatment (diacylglycerol-rich oil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: TG treatment (triacylglycerol-based control oil)
Number of subjects: 12
Study: 10683712

Group type: COMPARATOR
Intervention: Tramadol (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tilidine/naloxone (100 mg)
Number of subjects: 12
Study: 9170421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Pneumocystosis
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infection
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Toxoplasmosis
Number of subjects: 187
Study: 8400752

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trimethaphan (TMP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) and Trimethaphan (TMP)
Number of subjects: 26
Study: 2891369

Group type: EXPERIMENTAL
Intervention: Medetomidine (25, 50, and 100 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Medetomidine
Number of subjects: 8
Study: 29681059

Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus partial restoration (CTG + PR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 40
Study: 26017619

Group type: EXPERIMENTAL
Intervention: High level of financial disclosure
Number of subjects: 169

Group type: COMPARATOR
Intervention: Medium level of financial disclosure
Number of subjects: 169

Group type: COMPARATOR
Intervention: Low level of financial disclosure
Number of subjects: 169
Study: 25086065

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied with autologous thrombin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 54
Study: 22670895

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 86

Group type: COMPARATOR
Intervention: Valacyclovir
Number of subjects: 86
Study: 19270472

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: acamprosate
Number of subjects: 169

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study: 17766737

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-administration of non-opioid analgesics (gabapentin and/or rofecoxib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine use during the four hours preceding 8 a.m.
Number of subjects: 0
Study: 15028130

Group type: EXPERIMENTAL
Intervention: Urokinase (25000 international units at 12-hour intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 12
Study: 11798981

Group type: EXPERIMENTAL
Intervention: Steroids (mainstay of therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative agents (under investigation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9825257

Group type: EXPERIMENTAL
Intervention: Conventional PPV
Number of subjects: 36
Study: 7854794

Group type: EXPERIMENTAL
Intervention: Epidural somatostatin 125 micrograms every hour
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo: mannitol 2.5 mg
Number of subjects: 40
Study: 2221484

Group type: EXPERIMENTAL
Intervention: Standardized wheat flour extract
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1265550

Group type: EXPERIMENTAL
Intervention: Orally administered prostaglandin E2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100
Study: 31055222

Group type: EXPERIMENTAL
Intervention: High-dose EPA and DHA (3.36 g daily)
Number of subjects: 218

Group type: COMPARATOR
Intervention: No omega-3
Number of subjects: 218
Study: 25983310

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) including OptiVol and predefined management of alerts
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard in-office visits every 3 months (control group)
Number of subjects: 176
Study: 23607962

Group type: EXPERIMENTAL
Intervention: Web-based stress intervention (13 sessions over 1 month)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control condition (no intervention during the study period)
Number of subjects: 259
Study: 21664412

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 62
Study: 19419755

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration with ADP 5 microM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration with ADP 20 microM
Number of subjects: 120

Group type: COMPARATOR
Intervention: ADP 5 microM (without clopidogrel)
Number of subjects: 120

Group type: COMPARATOR
Intervention: ADP 20 microM (without clopidogrel)
Number of subjects: 120
Study: 16192658

Group type: EXPERIMENTAL
Intervention: Self-reported moderate activity
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Self-reported flexibility
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Self-reported strength
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Estimated VO(2max) classification
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Adherence to Healthy People 2010 targets for moderate activity and strengthening
Number of subjects: 225
Study: 12859476

Group type: EXPERIMENTAL
Intervention: Propofol drawn up and injected through an unfiltered plastic cannula
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol drawn up through a 5-microm filter needle and injected through an unfiltered plastic cannula
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol drawn up and injected through a 5-microm filter needle
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (unfiltered plastic cannula)
Number of subjects: 120
Study: 10190873

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy (90Sr/Y source train, 12, 14, or 16 Gy at 2 mm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy
Number of subjects: 30
Study: 8525689

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine regimen with two injections four weeks apart
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine regimen with two injections eight weeks apart
Number of subjects: 757
Study: 2407162

Group type: EXPERIMENTAL
Intervention: Debridement and wound care
Number of subjects: 163

Group type: COMPARATOR
Intervention: Wound care alone
Number of subjects: 163
Study: 7387147

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 26
Study: 31960719

Group type: EXPERIMENTAL
Intervention: Combined group with both epidural blockade and parecoxib
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Epidural blockade group
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 31813359

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A plus evidence‐based movement training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Botulinum toxin‐A plus handout of exercises
Number of subjects: 140
Study: 28527615

Group type: EXPERIMENTAL
Intervention: Touch technique (T)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No-touch technique (NT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Touch technique (T) after crossover
Number of subjects: 300

Group type: COMPARATOR
Intervention: No-touch technique (NT) after crossover
Number of subjects: 300
Study: 28198091

Group type: EXPERIMENTAL
Intervention: 24-month DAPT
Number of subjects: 604

Group type: COMPARATOR
Intervention: 6-month DAPT
Number of subjects: 604
Study: 25637334

Group type: EXPERIMENTAL
Intervention: Up-and-reach (UR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Forward reach (FR)
Number of subjects: 42
Study: 23026132

Group type: EXPERIMENTAL
Intervention: Genetic variants in the leptin gene (17 SNPs)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Meta-analysis combining MARS, GENDEP, and STAR(⁎)D studies
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Leptin mRNA expression and serum levels
Number of subjects: 609
Study: 20889289

Group type: EXPERIMENTAL
Intervention: Sedation protocol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sedation protocol with daily sedative/analgesic interruption
Number of subjects: 21
Study: 18178380

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: D-ribose (2000 mg/d)
Number of subjects: 17
Study: 16918591

Group type: EXPERIMENTAL
Intervention: Metformin (M) 1700 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (T) 600 mg/day
Number of subjects: 20
Study: 16036074

Group type: EXPERIMENTAL
Intervention: Highly potent bisphosphonates
Number of subjects: 0
Study: 10932487

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 and IGFBP-3 concentrations in GHD children
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serum IGF-1 and IGFBP-3 concentrations in NVSS children
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IGF-1 and IGFBP-3 levels transformed to standard deviation score (SDS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined use of IGF-1 and IGFBP-3 < -2 SDS
Number of subjects: 60